专题：Radiopharmaceutical Chemistry and Applications

This cluster of papers focuses on the development, synthesis, and application of radiopharmaceuticals for PET and SPECT imaging, targeted therapy, radioimmunotherapy, and alpha particle therapy in cancer treatment. It covers topics such as coordinating radiometals, chelators, dosimetry, and the use of specific radionuclides for therapeutic purposes.
最新文献
Activation of Small Molecules by Modified Dodecaborate Anions

article Full Text OpenAlex

Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody–Drug Radioconjugate

article Full Text OpenAlex

From cyclotrons to chromatography and beyond: a guide to the production and purification of theranostic radiometals

review Full Text OpenAlex

Cobaltabis(dicarbollide) Interaction with DNA Resolved at the Atomic Scale

article Full Text OpenAlex

All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful

article Full Text OpenAlex

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies

review Full Text OpenAlex

The applications of radioisotopes in modern medicine: a review of diagnostic, therapeutic, and research advancements

review Full Text OpenAlex

Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer

article Full Text OpenAlex

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving177Lu-PSMA-617

article Full Text OpenAlex

Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer

article Full Text OpenAlex

近5年高被引文献
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

article Full Text OpenAlex 2181 FWCI284.4121722

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

article Full Text OpenAlex 959 FWCI132.47805782

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 452 FWCI151.81874351

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

article Full Text OpenAlex 450 FWCI60.49064856

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

letter Full Text OpenAlex 425 FWCI30.20834855

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)

article Full Text OpenAlex 333 FWCI46.87140898

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

article Full Text OpenAlex 317 FWCI46.51766249

Molecular imaging in oncology: Current impact and future directions

review Full Text OpenAlex 316 FWCI33.25243943

Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection

article Full Text OpenAlex 311 FWCI42.44957794

Radiotheranostics in oncology: current challenges and emerging opportunities

review Full Text OpenAlex 301 FWCI58.77010317